A phase III trial to study Esophageal Adenocarcinoma

This study is being done to compare the effects, good and/or bad, of the addition of trastuzumab to standard chemotherapy, radiation, and surgery for patients with HER2 positive esophageal cancer.

I'M INTERESTED

This research study is led by Dr. Seth Kaufman.

Contact: Dawn DeMarinis, 413-794-4362

Participation details:

BH11-211
Cancer - Esophogus, Cancer
D’Amour Center for Cancer Care, 3350 Main Street, Springfield, MA

Participants must have confirmed esophageal cancer, HER2 positive, and no prior chemotherapy or radiation.

Active
Interventional (Clinical Trial), Randomized
3